Last reviewed · How we verify
Gemcitabine Injectable Product
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death.
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death. Used for Pancreatic cancer, Non-small cell lung cancer, Breast cancer.
At a glance
| Generic name | Gemcitabine Injectable Product |
|---|---|
| Also known as | nivolumab |
| Sponsor | Henan Cancer Hospital |
| Drug class | Nucleoside analog antimetabolite |
| Target | Ribonucleotide reductase; DNA incorporation |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Gemcitabine is a deoxycytidine analog that is phosphorylated intracellularly to its active diphosphate and triphosphate forms. It inhibits ribonucleotide reductase, reducing deoxyribonucleotide pools, and is incorporated into DNA where it causes chain termination and apoptosis. It is particularly effective against rapidly dividing cancer cells.
Approved indications
- Pancreatic cancer
- Non-small cell lung cancer
- Breast cancer
- Ovarian cancer
- Bladder cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Fatigue
- Fever
- Rash
- Dyspnea
- Hemolytic uremic syndrome
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] (PHASE2)
- Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C (PHASE1, PHASE2)
- A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine Injectable Product CI brief — competitive landscape report
- Gemcitabine Injectable Product updates RSS · CI watch RSS
- Henan Cancer Hospital portfolio CI